Meningococcal Disease Outbreak: Updates from Kent, UK and Ireland

An outbreak of meningococcal disease is currently underway in Kent, UK, prompting health officials to take preventative measures. As of March 18, 2026, 15 laboratory-confirmed cases have been identified, with an additional 12 notifications under investigation, bringing the total to 27. Tragically, two individuals have died as a result of the outbreak. Public health authorities are working to contain the spread and protect vulnerable populations.

Outbreak Details in Kent, UK

The UK Health Security Agency (UKHSA) is leading the investigation into the outbreak, which is primarily affecting young adults. Preventative antibiotic treatment is being administered to students at the University of Kent, as well as individuals who visited Club Chemistry in Canterbury between March 5th and 7th. Antibiotics are also available through GPs nationwide for those who may have been exposed. Confirmed cases have been identified in students at four schools in Kent and one higher education institution in London, linked to the Kent outbreak.

A targeted MenB vaccination program has begun for approximately 5,000 students and staff living or working in halls at the University of Kent Canterbury Campus. The program will be expanded as needed, based on ongoing risk assessments by the UKHSA. While the MenB vaccine offers protection against illness, it does not prevent individuals from carrying and spreading the bacteria.

Situation in Ireland

The Health Service Executive (HSE) in Ireland is closely monitoring the situation in the UK and maintaining regular contact with the UKHSA. As of March 19, 2026, there is no evidence of an increase in invasive meningococcal disease activity in Ireland beyond expected seasonal levels, nor are there any confirmed links between cases in Ireland and the outbreak in Kent.

In 2026 to date, 12 cases of meningococcal disease have been reported in Ireland, with no fatalities. Nine of these cases are Serogroup B. In comparison, 60 cases were reported in 2025 (38 Serogroup B) and 66 cases in 2024 (42 Serogroup B). Routine surveillance indicates that meningococcal disease remains rare but serious in Ireland.

Understanding Meningococcal Disease

Meningococcal disease is caused by bacteria and can lead to meningitis (inflammation of the brain’s lining) and septicaemia (blood poisoning). Several different serotypes of the bacteria exist, and vaccines are available for types A, B, C, W, and Y.

The disease can affect people of all ages, but is most common in babies, young children, and teenagers/young adults. Symptoms can develop rapidly and include:

• Fever
• Severe headache
• Vomiting
• Rapid breathing
• Cold hands and feet
• Drowsiness
• A rash that doesn’t fade under pressure

Important Note: Do not wait for a rash to appear. Seek immediate medical attention if someone is ill and their condition is worsening. Call emergency services (112 or 999) or go to the nearest emergency department.

Vaccination Information

The MenB vaccine is part of the national childhood immunisation schedule in Ireland for babies born from October 1, 2016, administered at 2, 4, and 12 months. There is currently no catch-up program for older children. The MenACWY vaccine is offered in the first year of secondary school, protecting against serogroups A, C, W, and Y.

For more information on the school immunisation program in Ireland, contact https://www2.hse.ie/screening-and-vaccinations/contact-a-local-immunisation-officer-lio/.